AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Purple Biotech Ltd.

Share Issue/Capital Change Dec 3, 2024

7004_rns_2024-12-03_da92b0f4-9091-45fb-9b00-e381a5fe6bea.htm

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

PR: Purple Biotech Announces $2.8 Million Registered Direct Offering of AmericanDepositary Shares false

���� ����� ��"� 2 380
PURPLE BIOTECH LTD
Corporation no: 520031238 12724
- - -
Israel Securities Authority Tel Aviv Stock Exchange C002 ( Public ) Reported via MAGNA: 03/12/2024
www.isa.gov.il www.tase.co.il Reference: 2024-02-621615 Time of broadcast: 15:32 15:32

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onPR: Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

ea022342801pr_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: [email protected]   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: [email protected] 1
Israel

Talk to a Data Expert

Have a question? We'll get back to you promptly.